Trial Profile
Active specific immunotherapy with the vaccine preparation NGcGM3 / VSSP in patients with small cell lung cancer
Status:
Recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 16 Oct 2020
Price :
$35
*
At a glance
- Drugs N-glycolyl GM3 vaccine (Primary)
- Indications Small cell lung cancer
- Focus Adverse reactions
- 29 May 2018 Status changed from not yet recruiting to recruiting.
- 17 Jan 2017 New trial record